{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:48:12Z","timestamp":1759333692975,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaad.2022.10.058","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T07:29:04Z","timestamp":1668151744000},"page":"e145-e146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to the article by Naik et\u00a0al entitled \u201canakinra for refractory pustular psoriasis: A phase II, open label, dose-escalation trial\u201d"],"prefix":"10.1016","volume":"88","author":[{"given":"Kazuki","family":"Yatsuzuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamoto","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2022.10.058_bib1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaad.2022.07.065","article-title":"Anakinra for refractory pustular psoriasis: a phase II, open label, dose-escalation trial","volume":"87","author":"Naik","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.10.058_bib2","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2022.10.058_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2022.10.058_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"issue":"8","key":"10.1016\/j.jaad.2022.10.058_bib5","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1038\/jid.2010.87","article-title":"Acrosyringium is the main site of the vesicle\/pustule formation in palmoplantar pustulosis","volume":"130","author":"Murakami","year":"2010","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222030006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222030006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:09:22Z","timestamp":1759273762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222030006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0190962222030006"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.10.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to the article by Naik et\u00a0al entitled \u201canakinra for refractory pustular psoriasis: A phase II, open label, dose-escalation trial\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.10.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}